{
    "eid": "2-s2.0-85077996683",
    "title": "Osimertinib-associated ashy dermatosis\u2013like hyperpigmentation",
    "cover-date": "2020-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Dermatology",
            "@code": "2708",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "ashy",
        "epidermal growth factor receptor inhibitor",
        "hyperpigmentation",
        "osimertinib",
        "rash"
    ],
    "authors": [
        "Pattamon Lertpichitkul",
        "Jade Wititsuwannakul",
        "Pravit Asawanonda",
        "Pawinee Rerknimitr"
    ],
    "citedby-count": 8,
    "ref-count": 10,
    "ref-list": [
        "Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer",
        "Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis",
        "Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: a meta-analysis",
        "Osimertinib: a review in T790M-positive advanced non-small cell lung cancer",
        "Management of dermatologic complications of lung cancer therapies",
        "Complications of therapy in cancer patients",
        "Ashy dermatosis: a review",
        "A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl's melanosis",
        "Esomeprazole-induced ashy dermatosis-like drug eruptions",
        "Literature review of treatment outcomes for lichen planus pigmentosus, erythema dyschromicum perstans, and ashy dermatosis"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Chulalongkorn University"
    ]
}